{
    "clinical_study": {
        "@rank": "114242", 
        "acronym": "M22", 
        "arm_group": {
            "arm_group_label": "rHIgM22", 
            "arm_group_type": "Placebo Comparator", 
            "description": "Cohorts 1-5: In each dosing cohort, the first 2 eligible patients will be enrolled and randomized 1:1 to receive rHIgM22 or placebo, and monitored for safety for a minimum of 7 days before the remaining 8 patients in the cohort are randomized (7 active: 1 placebo) and dosed.\nExpanded Cohort: Upon establishment of a Maximally Tolerated Dose (MTD), a new group of 21 patients will be enrolled in an Expansion Cohort. Randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: placebo, Investigational Product (IP) at MTD, or IP at one full dose level lower than MTD."
        }, 
        "brief_summary": {
            "textblock": "This is a Phase I, multi-center, double-blind, randomized, placebo-controlled,\n      dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and\n      immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all\n      clinical presentations of MS."
        }, 
        "brief_title": "An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to give written informed consent, with adequate cognitive function to sign the\n             IRBapproved informed consent\n\n          -  Meet diagnostic criteria for MS, as defined by revised (2010) McDonald criteria\n\n          -  Man or woman aged 18 to 70 years, inclusive\n\n          -  Women of childbearing potential must have a negative serum pregnancy test at the\n             Screening Visit and\n\n          -  Women of childbearing potential and engaged in heterosexual relations must agree to\n             practice adequate contraception for at least 60 days after study dosing. Women of\n             childbearing potential and not engaged in heterosexual relations or not practicing\n             adequate contraception must agree to remain abstinent for at least 60 days after\n             study dosing practice adequate contraception for the duration of the study\n\n          -  Agree to remain in the hospital for the 48 hour post infusion observation period, and\n             can be contacted in case of an emergency once discharged\n\n        Exclusion Criteria:\n\n          -  Serum creatinine \u22651.5 mg/dL\n\n          -  Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) or alkaline\n             phosphatase \u22651.5 times the upper limit of normal\n\n          -  Angina, uncontrolled hypertension, clinically significant cardiac arrhythmias\n             (including atrial fibrillation), any other clinically significant cardiovascular\n             abnormality or clinically significant abnormal ECG\n\n          -  Immune-mediated disorder other than MS that in the Investigator's judgment, may\n             affect the interpretation of results or the patient's ability to safely complete the\n             study\n\n          -  Any clinically significant cardiac, endocrinologic, hematologic, hepatic,\n             immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,\n             renal, allergic or anaphylactic reasons, or other major diseases (other than MS),\n             that in the Investigator's judgment, may affect the interpretation of results or\n             patient's ability to safely complete the study. This includes a suicide attempt\n             within the past 1 year or severe suicidal ideation within the past 6 months or\n             patients who in the opinion of the Investigator are at significant risk of suicidal\n             behavior\n\n          -  MS relapse within 30 days prior to screening or treatment with systemic (oral, IV or\n             IM) corticosteroids, except for minimally absorbed topical or inhalational\n             preparations, within the 30 days prior to the Screening Visit\n\n          -  Initiation of interferon-beta 1b (Betaseron,a extavia), interferon beta-1a (Avonex, a\n             Rebif a), glatiramer acetate (copaxone), natalizumab (Tysabri), or fingolimod\n             (Gilenya), or dimethyl fumarate (Tecfidera \u00ae) within the 90 days prior to the\n             Screening Visit, or any change in the dosing regimen of these drugs within the 30\n             days prior to the Screening Visit. Initiation of teriflunomide (AUBAGIO\u00ae) or any\n             change in the dosing regimen of this drug within 90 days prior to the Screening\n             Visit.\n\n          -  Treatment with any of the following medications within the 12 months prior to Day 1\n             of the study: daclizumab, azathioprine, methotrexate, IV immunoglobulin,\n             plasmaphoresis, or mycophenolate mofetil; or discontinuation of teriflunomide\n             (AUBAGIO\u00ae) within 12 months prior to Day 1.\n\n          -  History of clinically significant infusion reactions with administration of\n             biologics, including plasma exchange, intravenous immunoglobulin, and other\n             monoclonal antibodies such as natalizumab (Tysabri)\n\n          -  Prior treatment with total lymphoid irradiation, T cell or T-cell receptor\n             vaccination, alemtuzumab, mitoxantrone, cyclophosphamide, or rituximab\n\n          -  Received any investigational agent or therapy up to 30 days or 4 pharmacokinetic\n             half-lives (whichever is longer) prior to Screening Visit or plans to enroll in\n             another investigational trial at any time during this study\n\n          -  Contraindication to brain MRI or inability to tolerate brain MRI"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "71", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803867", 
            "org_study_id": "IM22-MS-1004"
        }, 
        "intervention": {
            "arm_group_label": "rHIgM22", 
            "description": "Administered via IV infusion", 
            "intervention_name": "rHIgM22", 
            "intervention_type": "Drug", 
            "other_name": "M22"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "MS", 
            "Multiple Sclerosis"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }, 
                    "name": "Collaborative Neuroscience Network, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California Davis Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California at San Francisco (UCSF)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Denver"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Centennial", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80112"
                    }, 
                    "name": "IMMUNOe"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "University of Kansas Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21225"
                    }, 
                    "name": "Parexel International"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63131"
                    }, 
                    "name": "BJC Medical Group (Missouri Baptist Medical Center)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "University of Rochester Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02903"
                    }, 
                    "name": "Rhode Island Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "New Orleans Center for Clinical Research (NOCCR)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "University of Texas Southwestern Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Vermont", 
                        "zip": "05401"
                    }, 
                    "name": "Fletcher Allen Health Care"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "Virginia Mason Medical Center (VMMC)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98122"
                    }, 
                    "name": "Multiple Sclerosis Center, Swedish Neuroscience Institute"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)", 
        "overall_official": {
            "affiliation": "Acorda Therapeutics", 
            "last_name": "Enrique Carrazana, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Monitoring of adverse events (AEs) will be conducted throughout the study. Adverse events, including serious adverse events will be recorded in the case report forms (CRFs).", 
            "measure": "Safety and tolerability of single ascending doses of the human monoclonal rHIgM22 in patients with MS.", 
            "safety_issue": "No", 
            "time_frame": "90 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803867"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PK parameters will include; The maximum measured plasma concentration (Cmax), time to maximum plasma concentration (Tmax), half-life (T1/2), and the area under the concentration curve from time 0 to the concentration at last time point (AUC (0-last)).", 
                "measure": "Measure the pharmacokinetics (PK) of single ascending doses of rHIgM22", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 180"
            }, 
            {
                "measure": "Measure the pharmacodynamics of single ascending doses of rHIgM22 using the Expanded Disability Status Scale (EDSS)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 180"
            }
        ], 
        "source": "Acorda Therapeutics", 
        "sponsors": {
            "collaborator": {
                "agency": "PRA International", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Acorda Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}